Histologic remission of cardiac amyloidosis: A case report

Amyloid

Volumn 19, Issue 2, 2012, Pages 106-109

  Nelson, Matthew R ^a   Lanza, Louis A ^a   Reeder, Craig B ^a   Scott, Robert L ^a   McCullough, Ann E ^a   Chandrasekaran, Krishnaswamy ^a   Click, Roger L ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Biopsy; Cardiac amyloid; Echocardiography; Histologic regression

Indexed keywords

AMYLOID; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; MELPHALAN; THALIDOMIDE;

ADULT; AORTA VALVE REPLACEMENT; ARTICLE; CASE REPORT; DYSPNEA; ECHOCARDIOGRAPHY; ENDOCARDITIS; HEART AMYLOIDOSIS; HEART MUSCLE BIOPSY; HEART RIGHT BUNDLE BRANCH BLOCK; HEART VENTRICLE HYPERTROPHY; HUMAN; HUMAN TISSUE; KIDNEY AMYLOIDOSIS; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; REMISSION; SURVIVAL; TREATMENT RESPONSE;

AMYLOID; AMYLOIDOSIS; CARDIOMYOPATHIES; HUMANS; MALE; MIDDLE AGED; REMISSION INDUCTION; TRETOQUINOL;

EID: 84861626042     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.3109/13506129.2012.660892     Document Type: Article

References (11)

1. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45-59.
2. Ng B, Connors LH, Davidoff R, Skinner M, Falk RH. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med 2005;165:1425-1429.
3. Dubrey SW, Cha K, Anderson J, Chamarthi B, Reisinger J, Skinner M, Falk RH. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 1998;91:141-157.
4. Murtagh B, Hammill SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol 2005;95:535-537.
5. Kristen AV, Perz JB, Schonland SO, Hansen A, Hegenbart U, Sack FU, Goldschmidt H, et al. Rapid progression of left ventricular wall thickness predicts mortality in cardiac light-chain amyloidosis. J Heart Lung Transplant 2007;26:1313-1319.
6. Comenzo RL, Vosburgh E, Falk RH, Sanchorawala V, Reisinger J, Dubrey S, Dember LM, et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 1998;91:3662-3670.
7. Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, Anderson JJ, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004;140:85-93.
8. Palladini G, Perfetti V, Obici L, Caccialanza R, Semino A, Adami F, Cavallero G, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004;103:2936-2938.
9. Kastritis E, Wechalekar AD, Dimopoulos MA, Merlini G, Hawkins PN, Perfetti V, Gillmore JD, Palladini G. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 2010;28:1031-1037.
10. Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 2007;109:457-464.
11. Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997;336:1202-1207.